Results with Rituxan
Rituxan is the first and only FDA-approved therapy that can help control a flare and put your disease into remission. Talk with your doctor to see if Rituxan may be right for you.
Proven to put GPA and MPA into complete remission
The Rituximab in ANCA-Associated Vasculitis (RAVE) trial was conducted with support from the National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network to see if Rituxan worked as well as cyclophosphamide in bringing on complete remission* in adults with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA).
The RAVE trial showed that 64% of people taking Rituxan achieved complete remission by 6 months and that Rituxan worked just as well as cyclophosphamide, the standard of care. In addition, there were no major differences between the overall side effects of Rituxan and cyclophosphamide.
Common side effects of Rituxan include infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema (swollen hands and feet). Other more serious side effects may include serious infections, progressive multifocal leukoencephalopathy (PML), severe infusion reactions, tumor lysis syndrome (TLS), and severe skin reactions.
- In this trial, "complete remission" was defined as no disease activity and no need for steroid therapy.